Studies on Kallikrein and Blood Pressure
スポンサーリンク
概要
- 論文の詳細を見る
Plasma kallikrein is known as a hypotensive factor in blood, which originates from kallikreinogen, and its action is due to formation of plasma kinin from kininogen. On the activation of kallikreinogen and the kinin formation, highly complicated mechanisms have been proposed by several authors. In our previous studies (1, 2), it was reported that not only kallikrein but also plasmin release kinin directly from kininogen, and no conversion of kallikreinogen into kallikrein by purified plasmin was observed under our experimental conditions. Moreover, Hageman factor, which was purified from bovine plasma, could convert kallikreinogen into kllikrein, but not plasminogen into plasmin. From these results, it was suggested that kinin formation in plasma is due to the action of kallikrein activated by Hageman factor or contact factor, and plasmin activated by tissue activator or bacterial product, such as streptokinase.<BR>On kininogen, it was found that in plasma there exist two types of kininogen, I andII, which are separated from each other with DEAE-Sephadex A-50 column chromatography (3): kininogen I is not adsorbed on the resin and kininogen II is adsorbed. Actions of various kinin forming enzymes on these two types of kininogen were examined and the kinin formed was determined by means of uterus of rat. Trypsin, plasmin and kallikrein activated by acetone treatment released kinin from both types of kininogen. However, the release of kinin from kininogen I by kallikrein activated by acetone was smaller than that from kininogen II. On the other hand, the kinin formation by kallikrein activated by Hageman factor was observed only from kininogen I and not from kininogen II. These results show the different kinin forming activities of these enzymes, and, particulary, between kallikrein activated by acetone treatment and that by Hageman factor.<BR>Various animal tissues contain a kallikrein inhibitor, and that found in lung is known under the trade name of "Trasyrol". In our present experiments, an inhibitor specific for kallikrein was observed in human plasma, and it was partially purified. The kallikrein inhibitor rapidly lost its activity at a temperature higher than 50°C. It was non-dialyzable, precipitated dy 0.6 saturation with ammonium sulfate, and has no effect on the esterolytic activity of plasmin. One KIU was designated as the amount of inhibitor which inhibits one mole of tosyl-L-arginine methyl ester TAMe hydrolyzing activity of kallikrein for 30min. at 37°C and pH 7.4. By using gel filtration of human plasma with Sephadex G-150, two types of kallikrein inhibitors were found. One was fastly eluated and inhibited TAMe hydrolytic activity of kallikrein (activated by acetone) specifically, and the other, which is lately eluated, inhibited the esterolytic activities of kallikrein and thrombin. The fast eluated fraction was applied to DEAE-cellulose column chromatography, and eluated with a gradient of increasing ionic strength using 0.017 M Tris, pH 7.3 and the same buffer containing 0.3 M NaCl. The specific activity of the most highly active fraction was 100 times of that of the original plasma. This purified kallikrein inhibitor decreases not only esterolytic activity of kallikrein but also hypotensive activity of kallikrein. Further studies will be required to elucidate the difference of this inhibitor from trasyrol and the inhibitor of C<SUB>1</SUB>-esterase in plasma.
- Japan Society of Clinical Chemistryの論文
著者
-
藤井 節郎
徳島大学医学部酵素研究施設
-
村松 睦
徳島大学医学部酵素生理
-
安倍 文計
徳島大学医学部第1外科
-
堤 健
徳島大学医学部附属酵素研究施設酵素生理
-
藤井 節郎
徳島大学医学部附属酵素研究施設酵素生理
-
安倍 文計
徳島大学医学部附属酵素研究施設酵素生理
-
村松 睦
徳島大学医学部附属酵素研究施設酵素生理
関連論文
- 制癌剤1-(2-Tetrahydrofuryl)-5-fluorouracil(FT一207), の生体内運命(第3報)直腸内投与による吸収, 体内分布, 排泄および代謝
- 4. C1-inhibitorの精製および抗原抗体反応における役割(第9回補体シンポジウム)
- 11.C1エステラーゼおよびプロC1sの精製(第8回補体シンポジウム)
- 1. C1の研究(第9回補体シンポジウム)
- 医学におけるリパーゼとその意義
- 鎖肛を伴わない直腸腟前庭瘻の考察 : 類似病態と新病型分類の提唱
- Studies on Kallikrein and Blood Pressure
- Regulation of Lipid Metabolism and Modified Enzyme
- Role of Enzymes in Inflammation
- Mechanism of ACTH Action in Corticosteroidogenesis of Rat Adrenal
- Regulatory Mechanism of Fatty Acid Metabolism
- Studies on Leucine Aminopeptidase
- Biological Role of Cl-esterase
- Studies on Hageman Factor, Plasmin and Kallikrein
- Mechanism of Adrenaline Induced Lipolysis and CyclicAMP
- Study on Clearing Factor Lipase
- Mechanism of ACTH Action
- Purification of Proteolytic Enzymes in Plasma and Other Enzymes by Affinity Chromatography
- New Methods for Determination of Various Plasma Deaminases and their Clinical Applications